Properties | Information | |
---|---|---|
PhytoCAT-ID | PhytoCAT-1722 | |
Phytochemical name or plant extracts | Arnicolide D | |
PMID | 32669950 | |
Literature evidence | Based on our findings, AD is a promising candidate for development as an adjunctive therapeutic drug for TNBC. © The author(s). | |
IUPAC name | [(1S,3aR,5R,5aR,8aR,9S,9aR)-1,5,8a-trimethyl-2,8-dioxo-3a,4,5,5a,9,9a-hexahydro-1H-azuleno[6,5-b]furan-9-yl] 2-methylprop-2-enoate | |
Phytochemicals’ class or type of plant extracts | Sesquiterpene lactone | |
Source of phytochemicals or plant Extracts | Centipeda minima | |
Geographical availability | Amur, Andaman Is., Assam, Bangladesh, Borneo, Cambodia, China North-Central, China South-Central, China Southeast, East Himalaya, Fiji, Hainan, India, Inner Mongolia, Japan, Jawa, Khabarovsk, Korea, Laos, Lesser Sunda Is., Malaya, Manchuria, Myanmar, Nansei-shoto, Nepal, New Caledonia, New Guinea, New South Wales, New Zealand North, New Zealand South, Northern Territory, Pakistan, Philippines, Primorye, Qinghai, Queensland, Samoa, Society Is., South Australia, Sri Lanka, Taiwan, Thailand, Tibet, Tonga, Vanuatu, Victoria, Vietnam, Western Australia, Xinjiang | |
Plant parts | NA | |
Other cancers | Breast cancer | |
Target gene or protein | NA | |
Gene or Protein evidence | NA | |
Target pathways | Akt/mTOR and STAT3 signaling pathways | |
IC50 | At 24h, 48h, 72h: 12.04 μM, 5.211 μM, 3.258 μM against MDA-MB-231 respectively 9.507 μM, 3.405 μM, 2.515 μM against MDA-MB-468 respectively 15.19 μM, 3.405 μM, 8.909 μM against MCF-7 respectively | |
Potency | Based on our findings, AD is a promising candidate for development as an adjunctive therapeutic drug for TNBC. | |
Cell line/ mice model | MDA-MB-231 xenograft mouse model, MDA-MB-231, MDA-MB-468 | |
Additional information | NA | |
PubChem ID | 182199 | |
Additional PMIDs | NA | |
Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:191968-1 | |
Safety | NA |